BioSpace News Archive

Apnimed, Inc. announced the company will participate in the following investor conferences in November 2023:

23andMe presented data from the now completed dose escalation phase, and pharmacokinetic / pharmacodynamic (PK/PD) cohorts at the Society for Immunotherapy of Cancer Annual Meeting 2023.

Akari Therapeutics, Plc today announced that Chief Scientific Officer Miles Nunn will present a poster titled Development of PASylated ® -Nomacopan for Treatment of Geographic Atrophy (GA) Secondary to Dry Age-Related Macular Degeneration (dAMD) at the 4th Annual Dry AMD Therapeutic Development conference.

T-knife Therapeutics, Inc. today announced the appointment of Simone Silva Steiner, Ph.D., to the role of Chief Technical Operations Officer.

Genevant Sciences, a leading nucleic acid delivery company with world-class platforms and an expansive lipid nanoparticle (LNP) patent portfolio, today announced that it has entered into a collaboration and nonexclusive license agreement with Novo Nordisk to combine Genevant’s proprietary LNP technology with innovative mRNA-based megaTAL technology to develop an in vivo gene editing treatment for hemophilia A.

Soleno Therapeutics, Inc. today announced publication of one-year results from the Phase 3 DESTINY PWS study and the open-label extension period of Study C602 evaluating investigational, once-daily DCCR (Diazoxide Choline) Extended-Release tablets for patients with Prader-Willi syndrome (PWS).

Indaptus Therapeutics, Inc. announces interim data from the first cohort of four patients in the Phase 1 INDP-D101 trial of its lead compound, Decoy20.

Enzo Biochem, Inc. (NYSE: ENZ) (“Enzo” or the “Company”) today announced financial results for the fourth quarter ended July 31, 2023, and the fiscal year ended July 31, 2023, and also provided a general business update.

Immutep Limited today announces the open-label safety lead-in of its integrated AIPAC-003 Phase II/III trial evaluating for the very first time 90mg of eftilagimod alpha (efti) in combination with paclitaxel has been completed with no safety or tolerability issues.

Aclarion, Inc. announced that Roger Hartl, M.D., Hansen-MacDonald Professor of Neurological Surgery and Director of Spinal Surgery at the Weill Cornell Brain and Spine Center in New York, as well as the co-director of New York-Presbyterian Och Spine, will advise the company as a key opinion leader nationally.